Brown, Darron R.Castellsagué, XavierFerris, DaronGarland, Suzanne M.Huh, WarnerSteben, MarcWheeler, Cosette M.Saah, AlfredLuxembourg, AlainLi, SeVelicer, Christine2023-07-072023-07-072022Brown DR, Castellsagué X, Ferris D, et al. Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young women. Tumour Virus Res. 2022;13:200236. doi:10.1016/j.tvr.2022.200236https://hdl.handle.net/1805/34216Background: Estimates of the humoral immune response to incident human papillomavirus (HPV) infections are limited. Methods: In this post hoc analysis of 3875 women aged 16-23 years from a 4-valent HPV vaccine trial (NCT00092482), HPV seroprevalence on day 1 was measured with a 9-valent HPV (HPV 6/11/16/18/31/33/45/52/58) competitive Luminex immunoassay and compared with cervical/external genital HPV detection by polymerase chain reaction. In the control group, among women who were HPV DNA‒negative on day 1, seroconversion following initial HPV detection was estimated using Kaplan-Meier methods. Results: Type-specific HPV seropositivity among women with no day 1 cervical/external genital HPV detection was 0.6%-3.6%. Women with any 9-valent HPV (9vHPV) cervical/external genital detection (796/3875; 20.5%) had concordant seropositivity ranging from 13.4% (HPV 45) to 38.5% (HPV 6). Among women in the control group who were negative for all HPV types on day 1, seroconversion by month 30 after initial detection ranged from 29% (HPV 45) to 75% (HPV 16). Conclusions: Humoral immune response to HPV is variable and dynamic, depending on type-specific exposure. This longitudinal analysis provides insight into the relationship between incident infection and seropositivity.en-USAttribution-NonCommercial-NoDerivatives 4.0 InternationalHuman papillomavirusHPV serologyHPV vaccinesHPV infectionSeroconversionSeroprevalenceArticle